Digital Health Acquisition Corp. (DHAC)

Dr. Tsay Brings Unique Expertise in AI, Digital Health, and Clinical Innovation to Counterpart Health Dr. Tsay Brings Unique Expertise in AI, Digital Health, and Clinical Innovation to Counterpart Health

BOCA RATON, Fla.--(BUSINESS WIRE)--Digital Health Acquisition Corp. (Nasdaq: DHAC), a Special Purpose Acquisition Company (SPAC), today announced the closing of its previously announced business combination consisting of the merger of Digital Health Acquisition Corp. with each of VSee Lab, Inc. and iDoc Virtual Telehealth Solutions, Inc. In connection with the closing, Digital Health Acquisition Corp. has been renamed VSee Health, Inc. (“VSee Health”), and effective with the start of trading on.

MEXICO CITY, MEXICO / ACCESSWIRE / May 20, 2024 / In a significant move to revolutionize digital health and wellness in Mexico and Argentina, Shen.AI, a leader in Face-Scanning Technology for remote vital signs monitoring, is thrilled to announce its collaboration with VivaWell, a pioneering healthtech in Latin America. This partnership is set to redefine preventive health care and wellness, making advanced health monitoring accessible to corporations and individuals across Mexico and Argentina.Vivawell Face-Scanning Technology - ScanRisk Vivawell Face-Scanning Technology - ScanRiskVivaWell, known for its innovative approach to the healthcare industry, combines preventive care with personalized wellness solutions. As the first platform of its kind in Latam, VivaWell has already transformed the way people approach their health and well-being, expanding beyond traditional healthcare to improve quality of life and well-being through a digital strategy.The integration of Shen.AI's cutting-edge technology into VivaWell's platform will empower users with accurate, remote health assessments, accessible directly from their smartphones. This collaboration aims to enhance VivaWell's offerings, providing health insights and fostering a proactive culture of health monitoring among its users."Partnering with Shen.AI allows us to take a giant leap forward in our mission to offer a comprehensive and personalized health prevention model," said Eduardo Iglesias, Founder & CEO of VivaWell. "Shen.AI's technology aligns perfectly with our vision of redefining preventive healthcare, offering our users an unprecedented level of insight into their wellness."This strategic partnership is a testament to both companies' commitment to leveraging technology for health promotion, prevention, and improving life quality. With this cooperation, Shen.AI and VivaWell are set to pave the way for a new era of digital health in Mexico and Argentina, making preventive health care more accessible, engaging, and effective than ever before.For more information about Shen.AI and VivaWell and their groundbreaking partnership, please visit Shen.AI and VivaWell.com.mxAbout VivaWellVivaWell is a leading healthtech company that provides a comprehensive, preventive and personalized health and wellness platform in Latam. As a digital-first company, VivaWell is redefining healthcare and expanding its services to promote well-being and quality of life.About Shen.AIShen.AI enables remote vital signs monitoring only with a Smartphone, helping Digital Health providers offer comprehensive online care. Their solutions enable accurate, remote health assessments, revolutionizing personal health monitoring and care.Contact InformationAna Paula Cheuquel Marketing Manager cheuquel.ana@vivawellok.com 54962572284SOURCE: VivaWellView the original press release on newswire.com.

Results Published in the Journal Pathology Kameda Adopts Ibex's Galen Prostate and Galen Breast to Support Pathologists in Primary Diagnosis BOSTON and CHIBA, Japan, May 20, 2024 /PRNewswire/ -- Ibex Medical Analytics (Ibex), a global leader in AI-powered cancer diagnostics, and Kameda Medical Center (Kameda), a leading Japanese institute at the pinnacle of healthcare innovation, today announced the publication of a clinical study evaluating Ibex's Galen™ platform, published in the peer-reviewed journal Pathology1, which demonstrated excellent outcomes in detecting cancer and other pathologies in prostate and breast biopsies. The artificial intelligence (AI)-powered platform has subsequently been deployed at Kameda and is now supporting their pathologists in routine practice, integrated with their Philips IntelliSite Pathology Solution. "We were deeply impressed by Galen's performance in the study, that based on our validation, clearly showed how Ibex can support our clinicians in improving diagnostic quality and efficiency, and as a result we have decided to implement it routinely," said Prof. Junya Fukuoka, MD, PhD, Chair of the Department of Pathology at Kameda Medical Center, Chair of the Department of Pathology Informatics at Nagasaki University and the study's primary investigator. "Interestingly, Galen identified both malignant and non-malignant findings previously undetected by pathologists and we are proud to have become the first pathology department in Japan to use digital pathology and AI routinely for primary cancer diagnosis, significantly improving our pathologists' user experience and confidence." Cancer incidence in Japan is rising, with prostate and breast cancers being the most commonly diagnosed cancers in men and women respectively last year. As incidence grows and diagnosis becomes more complex in this era of precision medicine, accuracy is critical for enabling personalized and tailored therapies. This is further compounded by the global shortage of pathologists, resulting in unprecedented workloads, impacting diagnostic quality and turnaround time. Ibex helps overcome these challenges with AI-powered workflows and decision-support tools that pathologists use in their everyday practice. The study, and subsequent publication authored by Kris Lami, MD, PhD, evaluated the performance of Ibex's AI platform in detecting a broad range of pathologies in 100 breast and 100 prostate biopsies taken from a Japanese patient cohort. Ibex's platform demonstrated excellent outcomes, showcasing its ability to accurately detect both cancerous and non-cancerous features. During the study, Galen Prostate demonstrated high accuracy in detecting prostate adenocarcinoma with an Area Under the Curve (AUC) of 0.988. The AI algorithm was also highly accurate in cancer grading, specifically differentiating between low and medium/high-grade Gleason scores with an AUC of 0.994, as well as in identifying perineural invasion. In several cases, Galen Prostate's AI algorithm accurately identified higher Gleason scores than previously evaluated by a pathologist and unveiled previously undetected cancer, showcasing its potential to enhance diagnostic accuracy and reduce inter-observer variability. Similarly, Galen Breast showed high accuracy in detecting invasive breast cancer (AUC of 0.997) and in detecting ductal carcinoma in situ (DCIS) (AUC of 0.996), as well as in identifying other important pathologies, such as lymphovascular invasion. "We are proud to announce the study outcomes and publication led by such a prestigious Japanese medical center, which come as an addition to successful studies of Ibex's AI solutions recently presented by leading United States healthcare institutions across various tissue types," remarked Dr. Manuela Vecsler, VP of Clinical and Scientific Affairs at Ibex Medical Analytics. "Galen is the most widely deployed AI technology in pathology, and we are excited to see it adopted in Japan and become the new standard in cancer diagnosis, helping clinicians improve patient care." About Ibex Medical Analytics Ibex Medical Analytics (Ibex) is transforming cancer diagnostics with world-leading clinical grade AI-powered solutions for pathology. Empowering physicians and supporting pathologists, Ibex is on a mission to provide accurate, timely and personalized cancer diagnosis for every patient. Ibex's Galen™ is the first and most widely deployed AI-powered platform in pathology and demonstrated outstanding outcomes in multiple clinical studies2,3,4,5,6. Pathologists worldwide use Galen as part of their everyday routine practice to improve the accuracy of cancer diagnosis, implement comprehensive quality control measures, reduce turnaround times and boost productivity with more efficient workflows. For additional company information, please visit https://ibex-ai.com/ and follow us on LinkedIn and X. The Galen™ platform includes solutions which are for Research Use Only (RUO) in Japan and in the United States and not cleared by the FDA. Multiple Galen solutions are CE marked (IVDD and IVDR) and registered with the UK MHRA. For more information, including indication for use and regulatory approval in other countries, contact Ibex Medical Analytics. About Kameda Medical Center Kameda Medical Center is a network of medical services centered around Kameda General Hospital and Kameda Clinic, encompassing various facilities across multiple locations. As the flagship hospital in southern Chiba Prefecture, Kameda Medical Center offers a comprehensive range of medical services, from acute care to convalescent and home care. In 2009, Kameda became the first hospital in Japan to receive JCI accreditation, aiming to provide medical care to global standards. This commitment to world-class medical excellence continues today, and Kameda has been named one of Newsweek magazine's World's Best Hospitals for five consecutive years. The hospital is at the forefront of innovative challenges in the field of pathology, boasting one of the largest pathology teams in Japan. The Remote Image Digital Diagnosis Center, located at the Kameda Kyobashi Clinic in Tokyo, serves as a hub where top physicians from Nagasaki University, the Kameda Group, and around the globe collaborate and share knowledge in a virtual space. For more information, please visit our website: https://medical.kameda.com/general/en/. [1] Lami K et al., Validation of prostate and breast cancer detection artificial intelligence algorithms for accurate histopathological diagnosis and grading: a retrospective study with a Japanese cohort, Pathology, May 2024; https://doi.org/10.1016/j.pathol.2024.02.009 [2] Sandbank et al., Validation and real-world clinical application of an artificial intelligence algorithm for breast cancer detection in biopsies, npj Breast Cancer, December 2022 [3] Pantanowitz et al., An artificial intelligence algorithm for prostate cancer diagnosis in whole slide images of core needle biopsies: a blinded clinical validation and deployment study, THE LANCET Digital Health Aug 2020 [4] Rodriguez-Justo et al., Multi-Site Multi Reader Study on Artificial Intelligence-Assisted Primary Diagnosis of Gastric Biopsies, Virchows Arch (2023) 483 (Suppl 1): S1 [5] Comperat et al., Clinical Level AI-Based Solution for Primary Diagnosis and Reporting of Prostate Biopsies in Routine Use: A Prospective Reader Study, European Congress of Pathology 2021 [6] Raoux et al., Novel AI-Based Solution for Supporting Primary Diagnosis of Prostate Cancer Increases the Accuracy and Efficiency of Reporting in Clinical Routine, Modern Pathology (2021) 34 (suppl 2): 598-599 Logo - https://mma.prnewswire.com/media/1839936/Ibex_Logo.jpgLogo - https://mma.prnewswire.com/media/2416440/4714088/Kameda_Medical_Center_Logo.jpg

Digital Health Acquisition (NASDAQ:DHAC – Get Free Report) and KONE Oyj (OTCMKTS:KNYJY – Get Free Report) are both unclassified companies, but which is the better stock? We will compare the two companies based on the strength of their risk, profitability, earnings, institutional ownership, analyst recommendations, valuation and dividends. Institutional & Insider Ownership 1.0% of Digital Health Acquisition shares are held by institutional investors. 6.6% of Digital Health Acquisition shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Analyst Ratings This is a breakdown of recent ratings and target prices for Digital Health Acquisition and KONE Oyj, as reported by MarketBeat. Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Digital Health Acquisition 0 0 0 0 N/A KONE Oyj 1 3 1 0 2.00 Profitability This table compares Digital Health Acquisition and KONE Oyj’s net margins, return on equity and return on assets. Net Margins Return on Equity Return on Assets Digital Health Acquisition N/A N/A N/A KONE Oyj 8.62% 37.44% 10.96% Risk & Volatility Digital Health Acquisition has a beta of 0.02, indicating that its share price is 98% less volatile than the S&P 500. Comparatively, KONE Oyj has a beta of 0.69, indicating that its share price is 31% less volatile than the S&P 500. Earnings & Valuation This table compares Digital Health Acquisition and KONE Oyj’s top-line revenue, earnings per share and valuation. Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Digital Health Acquisition N/A N/A N/A N/A N/A KONE Oyj $11.85 billion 2.44 $1.00 billion $0.99 27.61 KONE Oyj has higher revenue and earnings than Digital Health Acquisition. Summary KONE Oyj beats Digital Health Acquisition on 6 of the 8 factors compared between the two stocks. About Digital Health Acquisition (Get Free Report) Digital Health Acquisition Corp. does not have significant operations. The company focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. It intends to focus on technology and healthcare focused businesses. Digital Health Acquisition Corp. was incorporated in 2021 and is based in Boca Raton, Florida. About KONE Oyj (Get Free Report) KONE Oyj, together with its subsidiaries, engages in the elevator and escalator business worldwide. The company provides elevators, escalators, and automatic building doors. It offers maintenance services; and modernization solutions. In addition, the company offers KONE Office Flow, a connected solution that allows for personalized user experiences and touch-free access; health and well-being solutions for elevators, escalators, and doors; KONE Access, an access control system, which is integrated with elevator system and building doors; KONE Destination, a destination control system that reduce waiting and travel times; KONE infotainment, a communication channel for building tenants and visitors; and monitoring solutions that enable real-time inspection of elevators and escalators. Further, it provides people flow planning and consulting services; solutions for special buildings and large projects; cybersecurity solutions; and energy solutions for greener buildings. KONE Oyj was founded in 1908 and is based in Espoo, Finland.

Boca Raton, FL, Oct. 27, 2023 (GLOBE NEWSWIRE) -- Digital Health Acquisition Corp. (the “Company” or “Digital Health”) (NASDAQ: DHAC), announced today that it received approval from the Nasdaq Stock Market (“Nasdaq”) to transfer the listing of its securities (including the common stock, units, and warrants) (the “Securities”) from the Nasdaq Global Market to the Nasdaq Capital Market. The Company's common stock, units and warrants will continue to trade under the symbols “DHAC,” “DHACU” and “DHACW,” respectively and the trading of its Securities will be unaffected by this transfer. This transfer will be effective as of the opening of business on October 30, 2023.